Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Athens University of Economics and Business - Research Center |
| Country | Greece |
| Start Date | Oct 01, 2022 |
| End Date | Sep 30, 2027 |
| Duration | 1,825 days |
| Number of Grantees | 12 |
| Roles | Participant; Coordinator; Associated Partner |
| Data Source | European Commission |
| Grant ID | 101057746 |
Radiotherapy is a widely used cancer treatment, however some patients suffer side effects. In breast cancer, side effects can include breast atrophy, arm lymphedema, and heart damage.
Some factors that increase risk for side effects are known, but current approaches do not use all available complex imaging and genomics data. The time is now ripe to leverage the huge potential of AI towards prediction of side effects.
This project will use rich datasets from three patient cohorts to design and implement an AI tool that predicts the risk of side effects, including arm lymphedema in breast cancer patients and provides an easily understood explanation to support shared decision-making between the patient and physician.
The PRE-ACT consortium combines the expertise in computing (MDW, AUEB-RC), AI (HES-SO, CENTAI), radiation oncology (MAASTRO, UNICANCER), medical physics (THERA), genetics (ULEIC), psychology (CNR) and health economics (UM) that is necessary to tackle this problem.The project will integrate data from the three cohorts and build AI predictive models with built-in explainability for each of the key side effects of breast cancer radiotherapy.
These AI models will be incorporated into an existing commercial radiotherapy software platform to create a world-leading product.
The extended platform will be validated in a clinical trial to support treatment decisions regarding the irradiation of lymph nodes.
The trial will adopt an innovative design in which the patients and medical team in the test arm will receive the risk prediction, but those in the control arm will not.
A communication package built with a co-design methodology will ensure that AI outcomes are tailored to stakeholders effectively.
The trial will evaluate whether using the AI platform changed the arm lymphedema rate and impacted treatment decisions and quality-of-life. Generalizability of the AI models for other types of cancer will be sought through transfer learning techniques.
Centai Institute Spa; Unicancer; Universiteit Maastricht; Stichting Maastricht Radiation Oncology Maastro Clinic; Consiglio Nazionale Delle Ricerche; Medical Data Works Bv; Istituto Per L'Interscambio Scientifico; Athens University of Economics and Business - Research Center; Haute Ecole Specialisee de Suisse Occidentale; University of Leicester; Therapanacea; Mirada Medical Ltd
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant